The latest focusIR Investor Webinar with speakers from: Pyx Resources, Helix Exploration, Fulcrum Metals and Metals One takes place on Tuesday 23rd July. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGenincode Regulatory News (GENI)

Share Price Information for Genincode (GENI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 5.65
Bid: 5.30
Ask: 6.00
Change: -0.10 (-1.74%)
Spread: 0.70 (13.208%)
Open: 5.625
High: 5.65
Low: 5.625
Prev. Close: 5.75
GENI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Collaboration with University Clinic Dresden

15 May 2023 07:00

RNS Number : 3343Z
15 May 2023

GENinCode Plc

("GENinCode" or the "Company")


Collaboration with University Clinic Dresden for implementation of LIPID inCode®

LIPID inCode® becomes first polygenic test for CVD implemented in Germany


Oxford, UK. GENinCode Plc (AIM: GENI), the predictive genetics company focused on the prevention of cardiovascular disease, announces its collaboration with the University Clinic Dresden, Department of Internal Medicine and Department of Human Genetics, based in Germany, to use its LIPID inCode® test in primary care for the diagnosis of hypercholesterolemia (high levels of cholesterol) and familial hypercholesterolemia ("FH"). LIPID inCode® is the first polygenic product to be introduced in Germany to improve the diagnosis and treatment of hypercholesterolemia to prevent cardiovascular disease ("CVD"). This new endeavour is based on a long-standing clinical research collaboration of GENinCode with the Department of Medicine (Prof. Dr. S. Bornstein).


The University Clinic lipid centre treats over 6000 patients with lipid disorders and constitutes the largest academic lipid apheresis centre globally. In Germany, 60% of the population suffer from high levels of cholesterol and it is estimated that over a quarter of a million of these cases relate to FH1. The collaboration also builds on the Transcampus Initiative between Technische Universität in Dresden and Kings College London, providing a translational model of best practice and patient care across borders.


LIPID inCode® testing will initially support the lipid centre in the region of Saxony to deliver its preventative care plans to identify individuals at risk of CVD. The lipid centre, will handle the regional roll-out of testing and may extend testing to other regions of Germany. LIPID inCode® improves the diagnosis and treatment of familial hypercholesterolemia with rapid turnaround of test results to prevent the onset of CVD. It is also the first commercially available polygenic test for CVD to be implemented in Germany. 


The collaboration follows the positive results of the LIPID inCode® Dresden clinical study and pilot. LIPID inCode® testing in the Saxony region will cover a primary care population and community practice in the region. Testing will diagnose patients with genetic disorders giving rise to high levels of cholesterol, an important risk factor for the development of CVD. Improved detection supports better treatment and preventative care.


In the Germany around 6 million people live with cardiovascular disease, which causes 25% of all deaths annually, with the disease rate particularly high in the region of Saxony2. CVD can be reduced by identifying and treating individuals at risk and the collaboration will focus on addressing CVD prevention, including identifying individuals with hypercholesterolemia and particularly those with FH.


FH is an inherited monogenic condition which affects an individual's ability to regulate and remove cholesterol from their blood. For individuals suffering with FH, it is important to lower cholesterol to healthy levels as early in life as possible, often requiring medicines such as statins or more aggressive treatment to help better control cholesterol levels.


GENinCode has a vision to assist clinicians and inform patients in interpreting cardiovascular risk, and to improve public health using the predictive capability of genomics. High genetic risk patients are assisted in making lifestyle choices and can receive targeted treatment to improve outcomes. Over the past 15 years GENinCode has made a substantial investment in its research, bioinformatic data, technology, and product development to assess disease risk, in order to help clinicians and patients prevent the onset of CVD.


Matthew Walls, CEO of GENinCode PLC, said: "The collaboration with the University Clinic in Dresden will focus on the use of Lipid inCode® testing to identify patients at high risk of heart disease, the largest cause of death in the Germany. The Dresden hub will handle regional testing and extend testing to other regions of Germany for the adoption of our globally leading polygenic test. We look forward to supporting the Dresden Lipid Centre in reaching its plans to provide early diagnosis of patients with hypercholesterolemia and prevent CVD."


Professor Stefan Bornstein, Chair and Director of Medicine of the University Hospital and Transcampus Dean Kings College London, commented: "We are delighted to collaborate with GENinCode to implement Lipid inCode® for the diagnosis and treatment of hypercholesterolemia and familial hypercholesterolemia. This collaboration marks a major step to improve our primary care practice for the identification of FH sufferers and we welcome this approach to work together with our UK colleagues as part of the German and UK Transcampus programme to reduce the onset of cardiovascular disease."


For more information visit



GENinCode Plc or via Walbrook PR

Matthew Walls, CEO

Stifel Nicolaus Europe Limited (Nomad and Joint Broker)

Tel: +44 (0)20 7710 7600

Alex Price / Ben Maddison / Richard Short


Cenkos Securities Plc (Joint Broker)


Tel: +44 (0)20 7397 8900

Giles Balleny

Dale Bellis / Michael Johnson (Sales)


Walbrook PR Limited

Anna Dunphy / Louis Ashe-Jepson / Phillip Marriage


Tel: 020 7933 8780 or


About GENinCode:

GENinCode Plc is a UK based company specialising in genetic risk assessment of cardiovascular disease. Cardiovascular disease is the leading cause of death and disability worldwide.


GENinCode operates business units in the UK, Europe through GENinCode S.L.U, and in the United States through GENinCode U.S. Inc.


GENinCode predictive technology provides patients and physicians with globally leading preventative care and treatment strategies. GENinCode CE marked invitro-diagnostic molecular tests combine clinical algorithms and bioinformatics to provide advanced patient risk assessment to predict disease onset.


About University Clinic Dresden, Department of Medicine and Department of Human Genetics:

The University Clinic Dresden, Department of Internal Medicine III, under the direction of Clinic Director Prof. Dr. Stefan R. Bornstein - with more than 250 employees in medical, nursing, technical and administrative services as well as in research - is one of the leading centres in Germany and Europe in the field of treatment and research of diabetes mellitus type 1 and 2 as well as its secondary diseases and lipid disorders. The clinic is home to the only active islet cell transplantation programme in Germany at present, the interdisciplinary vascular centre and the special outpatient clinics for rheumatology, metabolism, diabetic foot, insulin pumps, angiology, nephrology, endocrinology as well as the emergency room and the intensive care unit of internal medicine. The department of human genetics has extensive expertise in the analysis of common and rare genetic diseases and is also an integral part of the cancer centre.


About cardiovascular disease (CVD)

CVD is a broad disease classification which encompasses conditions such as coronary artery disease (causing angina, heart attacks, heart failure), cerebrovascular disease (causing stroke, and some dementia), peripheral vascular disease (causing limb ischemia, and some chronic kidney disease) and venous thromboembolism. CVD is the leading cause of death and disability worldwide accounting for one in every four deaths in the United States. According to the US National Institutes of Health (NIH), by 2030, the global cost of CVD is set to rise to US$1,044 billion, from approximately US$863 billion in 2010, and is both a major health issue and global economic burden3.


1 Prevalence of dyslipidemia among adults in Germany: results of the German Health Interview and Examination Survey for Adults (DEGS 1)] - PubMed (

2 Regional Differences in the Prevalence of Cardiovascular Disease - PMC (

3 Data-driven quality improvement program to prevent hospitalisation and improve care of people living with coronary heart disease: Protocol for a process evaluation - PMC (








This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Date   Source Headline
27th Jun 20244:02 pmRNSResult of AGM
5th Jun 20245:17 pmRNSPosting of Annual Report and Notice of AGM
3rd Jun 20247:00 amRNSFinal Results
23rd May 20247:00 amRNSNotice of Results
1st May 20247:00 amRNSCARDIO inCode-Score presentation
26th Apr 20242:30 pmRNSGrant of Options & Surrender of Existing Options
4th Apr 202410:44 amRNSCARDIO inCode-Score® US study publication
21st Mar 202410:58 amRNSNew NICE Guidance for Ovarian Cancer
9th Feb 202410:00 amRNSHolding(s) in Company
15th Jan 20247:00 amRNSHolding(s) in Company
11th Jan 20242:49 pmRNSHolding(s) in Company
11th Jan 20242:30 pmRNSHolding(s) in Company
9th Jan 20241:30 pmRNSResult of GM and Total Voting Rights
28th Dec 20237:00 amRNSResult of Retail Offer
21st Dec 20236:25 pmRNSResult of Placing and Subscription
21st Dec 20234:59 pmRNSRetail Offer
21st Dec 20234:55 pmRNSPlacing and Subscription
29th Nov 20237:10 amRNSCARDIO inCode-Score 510(k) FDA submission update
29th Nov 20237:00 amRNSChange of Adviser
12th Oct 20237:00 amRNSShareSoc investor presentation
20th Sep 20237:00 amRNSHalf-year Report
13th Sep 20237:00 amRNSNotice of Results
30th Aug 20237:00 amRNSPresentation at European Society of Cardiology
16th Aug 202310:27 amRNSCARDIO inCode 510k filing
19th Jul 20237:00 amRNSCollaboration with US healthcare provider
30th Jun 20234:03 pmRNSResult of AGM
8th Jun 20231:31 pmRNSNotice of AGM and posting of Annual Report
6th Jun 20237:00 amRNSFinal Results
5th Jun 20237:00 amRNSNotice of Results
22nd May 20237:00 amRNSCARDIO inCode be presented at conference
15th May 20237:00 amRNSCollaboration with University Clinic Dresden
2nd May 20237:00 amRNSNHS LIPID inCode testing implementation
3rd Apr 20237:00 amRNSCARDIO InCode CPT PLA Code
13th Mar 20237:00 amRNSStatement re: Silicon Valley Bank
3rd Jan 20234:40 pmRNSSecond Price Monitoring Extn
3rd Jan 20234:35 pmRNSPrice Monitoring Extension
3rd Jan 20237:00 amRNSApproval of California state license
22nd Nov 20222:07 pmRNSIssue of Share Options
3rd Nov 20227:00 amRNSBritish Medical Journal publication
10th Oct 20226:23 pmRNSHolding(s) in Company
27th Sep 20227:00 amRNSHalf-year report
7th Sep 20227:00 amRNSNotice of results
26th Jul 20227:00 amRNSNHS implementation of Lipid inCode testing
23rd Jun 20222:37 pmRNSResult of AGM
23rd May 20224:06 pmRNSPosting of Annual Report and Notice of AGM
17th May 20227:00 amRNSFinal Results
3rd May 20227:00 amRNSNotice of Results
6th Apr 20227:00 amRNSDirector Appointment
23rd Mar 20227:00 amRNSIndiana University Medical School collaboration
15th Mar 20227:00 amRNSLipid inCode pilot

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.